Disease Detail

ID DOID:4001
Name ovarian carcinoma
Definition An ovarian cancer that has_material_basis_in epithelial tissue and is located_in the ovary.
Source DiseaseOntology.org
Alt Ids
Path disease disease of anatomical entity reproductive system disease female reproductive system disease female reproductive organ cancer ovarian cancer ovary epithelial cancer malignant ovarian surface epithelial-stromal neoplasm ovarian carcinoma
Path disease disease of anatomical entity reproductive system disease reproductive organ cancer female reproductive organ cancer ovarian cancer ovary epithelial cancer malignant ovarian surface epithelial-stromal neoplasm ovarian carcinoma
Path disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer female reproductive organ cancer ovarian cancer ovary epithelial cancer malignant ovarian surface epithelial-stromal neoplasm ovarian carcinoma
Path disease disease of anatomical entity reproductive system disease female reproductive system disease ovarian disease ovarian cancer ovary epithelial cancer malignant ovarian surface epithelial-stromal neoplasm ovarian carcinoma
Path disease disease of anatomical entity endocrine system disease gonadal disease ovarian disease ovarian cancer ovary epithelial cancer malignant ovarian surface epithelial-stromal neoplasm ovarian carcinoma
Path disease disease of anatomical entity endocrine system disease endocrine gland cancer ovarian cancer ovary epithelial cancer malignant ovarian surface epithelial-stromal neoplasm ovarian carcinoma
Path disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer ovarian cancer ovary epithelial cancer malignant ovarian surface epithelial-stromal neoplasm ovarian carcinoma
Path disease disease of cellular proliferation cancer cell type cancer carcinoma ovarian carcinoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown NMS-P937 ovarian carcinoma not applicable detail...
Unknown unknown BMS-906024 ovarian carcinoma not applicable detail...
Unknown unknown NMS-P715 ovarian carcinoma not applicable detail...
TP53 I195* TP53 R248Q ReACp53 ovarian carcinoma sensitive detail...
TP53 Y234C ReACp53 ovarian carcinoma sensitive detail...
TP53 Y327L ReACp53 ovarian carcinoma sensitive detail...
TP53 inact mut ReACp53 ovarian carcinoma sensitive detail...
KRAS Q61H Bevacizumab + Sorafenib ovarian carcinoma sensitive detail...
MET N375S Bevacizumab + Sorafenib ovarian carcinoma sensitive detail...
ERBB2 positive SYD985 ovarian carcinoma sensitive detail...
Unknown unknown Rucaparib ovarian carcinoma not applicable detail...
Unknown unknown Denileukin diftitox + Sirolimus ovarian carcinoma no benefit detail...
Unknown unknown Gemcitabine + MU380 ovarian carcinoma not applicable detail...
BRCA1 L392Qfs*5 Rucaparib ovarian carcinoma sensitive detail...
BRCA1 W1782* Rucaparib ovarian carcinoma sensitive detail...
BRCA1 L631Qfs*4 Rucaparib ovarian carcinoma sensitive detail...
BRCA1 N682* Rucaparib ovarian carcinoma sensitive detail...
Unknown unknown Disarib ovarian carcinoma not applicable detail...
Unknown unknown Veliparib + Topotecan ovarian carcinoma not applicable detail...
BRCA1 mutant Bevacizumab + Carboplatin + Paclitaxel ovarian carcinoma no benefit detail...
BRCA2 mutant Bevacizumab + Carboplatin + Paclitaxel ovarian carcinoma no benefit detail...
Unknown unknown SKLB-23bb ovarian carcinoma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00989651 Phase I Bevacizumab + Veliparib Carboplatin Paclitaxel Cisplatin Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting
NCT01174121 Phase II Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer Recruiting
NCT01248962 Phase II Carboplatin Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer Completed
NCT01281514 Phase I Carboplatin + Doxil + Everolimus Carboplatin, Pegylated Liposomal Doxorubicin Hydrochloride, and Everolimus in Treating Patients With Relapsed Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer Completed
NCT01504126 Phase I Propranolol Beta-Blocker / Ovarian Active, not recruiting
NCT01607905 Phase I Selinexor Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer Completed
NCT01669798 Phase II Nintedanib BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer Completed
NCT01849874 Phase III Binimetinib A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Active, not recruiting
NCT01936974 Phase II Gemcitabine + Bevacizumab + Cisplatin Gemcitabine + Bevacizumab + Oxaliplatin Gemcitabine + Bevacizumab + Carboplatin Gemcitabine + Bevacizumab (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma Terminated
NCT01940172 Phase I Conatumumab Birinapant Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer Completed
NCT01974765 Phase II Enzalutamide Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies Active, not recruiting
NCT02042430 Phase I Epacadostat INCB024360 Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting
NCT02059265 Phase II Dasatinib Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer Unknown status
NCT02098343 Phase Ib/II Carboplatin + Doxorubicin APR-246 + Carboplatin + Doxorubicin p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246 Active, not recruiting
NCT02101775 Phase II Gemcitabine MK-1775 + Gemcitabine Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting
NCT02101788 Phase II Topotecan Doxil + Letrozole + Tamoxifen + Paclitaxel Trametinib Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Active, not recruiting
NCT02121990 Phase I Cisplatin + Paclitaxel + Bevacizumab + Olaparib Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Active, not recruiting
NCT02122185 Phase II Metformin Paclitaxel + Carboplatin + Docetaxel Metformin Hydrochloride and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting
NCT02166905 Phase Ib/II poly ICLC DEC-205-NY-ESO-1 fusion protein vaccine Epacadostat DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission Recruiting
NCT02208375 Phase Ib/II Olaparib Capivasertib Vistusertib mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian Cancer Active, not recruiting
NCT02270372 Phase I Varlilumab ONT-10 Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer Completed
NCT02272790 Phase II MK-1775 + Carboplatin MK-1775 + Gemcitabine MK-1775 + Paclitaxel A Phase II Study Comparing AZD1775 + Chemotherapy Versus Chemotherapy Alone in Patients to Treat Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Active, not recruiting
NCT02283658 Phase II Everolimus + Letrozole Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Unknown status
NCT02431559 Phase Ib/II Aldoxorubicin + MEDI4736 + Motolimod A Phase 1/2 Study of Motolimod (VTX-2337) and MEDI4736 in Subjects With Recurrent, Platinum-Resistant Ovarian Cancer for Whom Pegylated Liposomal Doxorubicin (PLD) is Indicated Active, not recruiting
NCT02440425 Phase II Paclitaxel Pembrolizumab Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer Active, not recruiting
NCT02444793 Phase I Mogamulizumab + Utomilumab A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors Terminated
NCT02459301 Phase I IPH2201 Dose-Ranging Study of IPH2201 in Patients With High Grade Serious CA of Ovarian, Fallopian Tube or Peritoneal Origin Active, not recruiting
NCT02470585 Phase III Carboplatin Paclitaxel Veliparib Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting
NCT02485990 Phase Ib/II Olaparib Tremelimumab Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma) Recruiting
NCT02489006 Phase II Olaparib A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Recruiting
NCT02520115 Phase I Dexamethasone Valproic acid Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer Recruiting
NCT02571725 Phase Ib/II Tremelimumab Olaparib PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer Recruiting
NCT02608684 Phase II Cisplatin + Gemcitabine + Pembrolizumab A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer Recruiting
NCT02657928 Phase II Letrozole + Ribociclib Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal or Endometrial Cancer Active, not recruiting
NCT02659241 Phase I Adavosertib A Pilot Study of Induction Wee1 Inhibition in Ovarian Cancer Recruiting
NCT02661815 Phase I ACY-1215 + Paclitaxel Bevacizumab A Phase 1b Study of Weekly Paclitaxel And Oral Ricolinostat For The Treatment Of Recurrent Platinum Resistant Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer Active, not recruiting
NCT02665416 Phase I RO5520985 + RO7009789 Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors Recruiting
NCT02759588 Phase Ib/II GL-ONC1 GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent Ovarian Cancer Recruiting
NCT02764333 Phase II MEDI4736 + TPIV 200 TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer Active, not recruiting
NCT02835833 Phase I Bevacizumab + Nintedanib Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors Completed
NCT02960594 Phase I INO-1400 + INO-9012 INO-1400 hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse Completed
NCT03029403 Phase II Pembrolizumab + DPX-Survivac + Cyclophosphamide Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Recruiting
NCT03435640 Phase Ib/II NKTR-214 + NKTR-262 Nivolumab + NKTR-214 + NKTR-262 A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies Recruiting